Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Consolidated revenue from operations stood at Rs. 111.05 crore
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The antibody was designed and developed at Abzena’s Cambridge, UK,
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Subscribe To Our Newsletter & Stay Updated